However, a recent biomarker study in patients with ovarian cancer treated with atezolizumab or placebo and standard chemotherapy found that deleterious mutations in RB1 were prognostic for a better PFS, regardless of the addition of atezolizumab (95). Here, RB1 is linked to ovarian carcinoma.